Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
(Added more current Clinically Feasible version) |
|||
Line 32: | Line 32: | ||
| [[Media:QIBA CTA Comments (02.16.2023).xlsx| Clinically Feasible Comment Resolutions 2023-02-16]] | | [[Media:QIBA CTA Comments (02.16.2023).xlsx| Clinically Feasible Comment Resolutions 2023-02-16]] | ||
|- | |- | ||
− | |CT Atherosclerosis 2023-03-28 | + | | [[Media:Atherosclerosis_Biomarkers_Profile_2023Mar28.pdf| CT Atherosclerosis 2023-03-28]] |
− | |Clinically Feasible | + | | Clinically Feasible |
− | |TBD | + | | TBD |
− | |Clinically Feasible Comment Resolutions 2023-03-28 | + | | [[Media:CTA_Profile_Clinically_Feasible_Comment_Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]] |
|- | |- | ||
| [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] | | [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] |
Revision as of 17:25, 29 March 2023
Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.